Back

Comprehensive assessment of disease status in ATTRwt-CM: Integrating serum transthyretin levels with clinical parameters using stabilizer therapy

30 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Heart failure redefined: hypertrophic cardiomyopathy and transthyretin amyloid cardiomyopathy precision treatments Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Assistant Professor Koji Yoshie

Shinshu University Hospital, Matsumoto (Japan)

6 More presentations in this session

Presentation thumbnail
Fewer adverse events reported in ATTR-CM patients treated with vutrisiran versus placebo: Post hoc safety analysis from HELIOS-B
Doctor S. Schwarting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Building on the demonstrated functional benefit of tafamidis: association of TTR stabilisation with 6MWT outcomes in ATTR ACT
Associate Professor M. Crespo-Leiro (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Estimated glomerular filtration rate trajectories by transthyretin stabilisation status in ATTR-ACT
Doctor S. Perlini (Pavia, IT)
Abstract Slides
Presentation thumbnail
Long-term efficacy of vutrisiran in patients with variant transthyretin amyloid cardiomyopathy
Doctor T. Zaizen (Oita, JP)
Abstract Slides
Presentation thumbnail
The importance of distinct cardiac MRI regional analyses to assess the effects of cliramitug on amyloid depletion from the Phase 1b study NI006-101
Doctor F. Aus Dem Siepen (Heidelberg, DE)
Abstract Slides

Access the full session

Session thumbnail
Heart failure redefined: hypertrophic cardiomyopathy and transthyretin amyloid cardiomyopathy precision treatments

The Event

Event poster

ESC Congress 2026

30 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension
30 August 2024
thumbnail
Congress Presentation
NT-proBNP and cardiopulmonary exercise testing parameters for risk stratification in ATTR-CM
5 April 2025
thumbnail
Congress Session
ATTR cardiomyopathy: from current practices to future treatment and monitoring
17 May 2025
thumbnail
Congress Presentation
Assessment of transthyretin tetramer stability in patients with ATTR‑CM using a novel probe‑based immunoassay
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources